Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 6/20 | 0.50 |
| ▸ | CCND1 | P24385 | 5/20 | 0.50 |
| ▸ | CDK2 | P24941 | 5/20 | 0.50 |
| ▸ | CCNE2 | O96020 | 4/20 | 0.50 |
| ▸ | CCNE1 | P24864 | 4/20 | 0.50 |
| ▸ | LTA4H | P09960 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | GAPDH | P04406 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 3/20 | 0.44 |
| ▸ | APAF1 | O14727 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7996516 | 0.81 | RPS6KA3 (0.47) | KDM4EKMT2AMEN1ALDH1A1HPGD | |
| SCHEMBL8008699 | 0.81 | KMT2A (0.50) | CDK4CCND1CDK2CCNE2CCNE1 | |
| SCHEMBL8887257 | 0.80 | LMNA (0.52) | CDK4CCND1CDK2CCNE2CCNE1 | |
| SCHEMBL22784037 | 0.79 | CCNE2 (0.46) | CDK4CCND1CDK2CCNE2CCNE1 | |
| SCHEMBL17279842 | 0.78 | HPGD (0.45) | CDK2KDM4EMAPTALDH1A1NPSR1 | |
| SCHEMBL8020401 | 0.77 | MAPT (0.67) | CDK4CCND1CDK2CCNE2CCNE1 | |
| SCHEMBL8889726 | 0.76 | ADORA3 (0.46) | LTA4HKDM4EMAPTKMT2AMEN1 | |
| SCHEMBL8888564 | 0.76 | ADORA3 (0.45) | LTA4HKDM4EMAPTKMT2AMEN1 | |
| SCHEMBL28102385 | 0.75 | MAPT (0.56) | CDK4CCND1CDK2CCNE2CCNE1 | |
| SCHEMBL28102260 | 0.75 | MAPT (0.56) | CDK4CCND1CDK2CCNE2CCNE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE39708-E1 | Estrogen receptor modulators | CHIRON CORPORATION (US) | 2007-06-26 | — | — | US | disclosed |
| EP-1102753-B1 | PYRAZOLES AS ESTROGEN RECEPTOR MODULATORS | NOVARTIS VACCINES & DIAGNOSTIC (US) | 2007-02-28 | — | — | EP | disclosed |
| US-6727273-B2 | THERAPY FOR OSTEOPOROSIS, ANTICANCER AGENTS | CHIRON CORPORATION | 2004-04-27 | — | — | US | disclosed |
| US-20040077701-A1 | Estrogen receptor modulators | CHIRON CORPORATION (US) | 2004-04-22 | — | — | US | disclosed |
| US-20040034081-A9 | ESTROGEN RECEPTOR MODULATORS | CHIRON CORPORATION | 2004-02-19 | — | — | US | disclosed |
| US-20020111374-A1 | Estrogen receptor modulators | CHIRON CORPORATION | 2002-08-15 | — | — | US | disclosed |
| US-6291505-B1 | PYRAZOLE ESTROGEN RECEPTOR AGONIST AND ANTAGONIST | CHIRON CORPORATION | 2001-09-18 | — | — | US | disclosed |
| EP-1102753-A2 | PYRAZOLES AS ESTROGEN RECEPTOR MODULATORS | CHIRON CORPORATION (US) | 2001-05-30 | — | — | EP | disclosed |
| WO-2000019994-A9 | ESTROGEN RECEPTOR LIGANDS | UNIV ILLINOIS (US) | 2000-08-31 | — | — | WO | disclosed |
| WO-2000019994-A1 | ESTROGEN RECEPTOR LIGANDS | BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2000-04-13 | — | — | WO | disclosed |
| WO-2000007996-A2 | PYRAZOLES AS ESTROGEN RECEPTOR MODULATORS | CHIRON CORPORATION (US) | 2000-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040077701-A1 | Estrogen receptor modulators | ESR1, ESR2, GPER1 | CDK4 395/4885CCND1 2661/4885CDK2 519/4885 |
| US-20040034081-A9 | ESTROGEN RECEPTOR MODULATORS | ESR1, ESR2, GPER1 | CDK4 395/4885CCND1 2661/4885CDK2 519/4885 |
| US-20020111374-A1 | Estrogen receptor modulators | ESR1, ESR2, GPER1 | CDK4 395/4885CCND1 2661/4885CDK2 519/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.